Mind Medicine Analyst Ratings
Mind Medicine Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/22/2023 | 68.67% | Cantor Fitzgerald | → $7 | Reiterates | Overweight → Overweight |
| 08/04/2023 | 1707.19% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 08/04/2023 | 68.67% | RBC Capital | $5 → $7 | Maintains | Outperform |
| 08/04/2023 | 406.01% | EF Hutton | → $21 | Reiterates | Buy → Buy |
| 07/10/2023 | 20.48% | RBC Capital | → $5 | Reiterates | Outperform → Outperform |
| 06/28/2023 | 1707.19% | HC Wainwright & Co. | $75 → $75 | Reiterates | Buy → Buy |
| 06/21/2023 | 20.48% | RBC Capital | → $5 | Reiterates | Outperform → Outperform |
| 06/20/2023 | 406.01% | EF Hutton | → $21 | Reiterates | Buy → Buy |
| 05/18/2023 | 68.67% | Cantor Fitzgerald | → $7 | Reiterates | → Overweight |
| 05/18/2023 | 406.01% | EF Hutton | → $21 | Reiterates | Buy → Buy |
| 05/09/2023 | 1707.19% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 05/05/2023 | 406.01% | EF Hutton | → $21 | Reiterates | → Buy |
| 04/18/2023 | 1707.19% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 04/14/2023 | 430.11% | Oppenheimer | → $22 | Reiterates | → Outperform |
| 04/14/2023 | 406.01% | EF Hutton | → $21 | Reiterates | → Buy |
| 03/16/2023 | 1707.19% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 03/10/2023 | 20.48% | RBC Capital | → $5 | Reiterates | → Outperform |
| 03/10/2023 | 406.01% | EF Hutton | → $21 | Reiterates | → Buy |
| 01/19/2023 | 1707.19% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 12/16/2022 | 406.01% | EF Hutton | → $21 | Initiates Coverage On | → Buy |
| 11/16/2022 | 20.48% | RBC Capital | → $5 | Initiates Coverage On | → Outperform |
| 09/21/2022 | 1707.19% | HC Wainwright & Co. | $5 → $75 | Maintains | Buy |
| 08/26/2022 | -15.66% | Oppenheimer | → $3.5 | Initiates Coverage On | → Outperform |
| 08/16/2022 | 20.48% | HC Wainwright & Co. | $10 → $5 | Maintains | Buy |
| 05/04/2022 | 68.67% | Roth Capital | → $7 | Initiates Coverage On | → Buy |
| 08/05/2021 | 140.96% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 06/28/2021 | 44.57% | Maxim Group | → $6 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月22日 | 68.67% | 康託·菲茨傑拉德 | →$7 | 重申 | 超重→超重 |
| 08/04/2023 | 1707.19% | HC Wainwright公司 | →$75 | 重申 | →購買 |
| 08/04/2023 | 68.67% | 加拿大皇家銀行資本 | $5→$7 | 維護 | 跑贏大盤 |
| 08/04/2023 | 406.01% | EF Hutton | →$21 | 重申 | 購買→購買 |
| 07/10/2023 | 20.48% | 加拿大皇家銀行資本 | →$5 | 重申 | 跑贏→跑贏大盤 |
| 2023年6月28日 | 1707.19% | HC Wainwright公司 | $75→$75 | 重申 | 購買→購買 |
| 2023年6月21日 | 20.48% | 加拿大皇家銀行資本 | →$5 | 重申 | 跑贏→跑贏大盤 |
| 06/20/2023 | 406.01% | EF Hutton | →$21 | 重申 | 購買→購買 |
| 2023年05月18日 | 68.67% | 康託·菲茨傑拉德 | →$7 | 重申 | →超重 |
| 2023年05月18日 | 406.01% | EF Hutton | →$21 | 重申 | 購買→購買 |
| 05/09/2023 | 1707.19% | HC Wainwright公司 | →$75 | 重申 | →購買 |
| 05/05/2023 | 406.01% | EF Hutton | →$21 | 重申 | →購買 |
| 04/18/2023 | 1707.19% | HC Wainwright公司 | →$75 | 重申 | →購買 |
| 04/14/2023 | 430.11% | 奧本海默 | →$22 | 重申 | →跑贏大盤 |
| 04/14/2023 | 406.01% | EF Hutton | →$21 | 重申 | →購買 |
| 03/16/2023 | 1707.19% | HC Wainwright公司 | →$75 | 重申 | →購買 |
| 03/10/2023 | 20.48% | 加拿大皇家銀行資本 | →$5 | 重申 | →跑贏大盤 |
| 03/10/2023 | 406.01% | EF Hutton | →$21 | 重申 | →購買 |
| 2023年1月19日 | 1707.19% | HC Wainwright公司 | →$75 | 重申 | →購買 |
| 12/16/2022 | 406.01% | EF Hutton | →$21 | 開始承保 | →購買 |
| 2022年11月16日 | 20.48% | 加拿大皇家銀行資本 | →$5 | 開始承保 | →跑贏大盤 |
| 2022/09/21 | 1707.19% | HC Wainwright公司 | $5→$75 | 維護 | 買 |
| 2022年08月26日 | -15.66% | 奧本海默 | →$3.5 | 開始承保 | →跑贏大盤 |
| 08/16/2022 | 20.48% | HC Wainwright公司 | $10→$5 | 維護 | 買 |
| 05/04/2022 | 68.67% | 羅斯資本 | →$7 | 開始承保 | →購買 |
| 08/05/2021 | 140.96% | HC Wainwright公司 | →$10 | 開始承保 | →購買 |
| 2021/06/28 | 44.57% | Maxim集團 | →$6 | 開始承保 | →購買 |
What is the target price for Mind Medicine (MNMD)?
精神藥物(MNMD)的目標價格是多少？
The latest price target for Mind Medicine (NASDAQ: MNMD) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $7.00 expecting MNMD to rise to within 12 months (a possible 68.67% upside). 23 analyst firms have reported ratings in the last year.
精神藥物(納斯達克：mnmd)的最新目標價是由坎託·菲茨傑拉德於2023年8月22日報道的。這家分析公司將目標價定為7.00美元，預計MNMD將在12個月內上漲(可能上漲68.67%)。過去一年，23家分析公司公佈了評級。
What is the most recent analyst rating for Mind Medicine (MNMD)?
精神醫學(MNMD)的最新分析師評級是多少？
The latest analyst rating for Mind Medicine (NASDAQ: MNMD) was provided by Cantor Fitzgerald, and Mind Medicine reiterated their overweight rating.
納斯達克(Sequoia Capital：MNMD)的最新分析師評級由康託·菲茨傑拉德提供，Mind Medicine重申其增持評級。
When is the next analyst rating going to be posted or updated for Mind Medicine (MNMD)?
Mind Medicine(MNMD)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mind Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mind Medicine was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Mind Medicine的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。精神醫學的上一次評級是在2023年8月22日提交的，所以你應該預計下一次評級將在2024年8月22日左右提供。
Is the Analyst Rating Mind Medicine (MNMD) correct?
分析師對精神醫學(MNMD)的評級正確嗎？
While ratings are subjective and will change, the latest Mind Medicine (MNMD) rating was a reiterated with a price target of $0.00 to $7.00. The current price Mind Medicine (MNMD) is trading at is $4.15, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的精神醫學(MNMD)評級被重申，目標價在0.00美元到7.00美元之間。Mind Medicine(MNMD)目前的交易價格為4.15美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。